Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Are you one of the LARGE bagholders holding 9 figures of shares?
Yup, a few LARGE bagholders trying to sucker in retail. Their plan isn't working. I'm impressed retail hasn't bought in to this scam. Too bad this CEO is so dumb and lazy. Come August 1, his opportunity will be gone. Instead of talking about Segwit and Hard fork and UASF, the guy would rather scam people for a measly 100k to pay off his debt to his vegas lawyer. What a complete moron. He could easily make millions leading up to August 1st but the moron has no clue. Idiot
Very glad retail isn't stupid enough to get scammed by this loser CEO.
News is gonna fail just like his website, with bitcoin ATM machines, and everything else this loser touches. He's a lazy moron only looking to make a quick $100k for himself and lawyer buddy. He could easily make millions. Complete idiot for blowing this opportunity for a measly $100k
Next week will be a bust. Look at your leader. Dumbest, laziest, moronic CEO ever. Bitcoin explodes up and all he does is tweet. What an idiot. And raise shares to make $100k when he could easily make millions if he wasn't so stupid. He's gotta pay off that crooked vegas lawyer though.
If you bought $1,000 worth of CCTL in 2010, it'd be worth about 50 cents today
Yeah, it only took a billion shares traded. What a scam. Dumbass CEO can't even get this scam shell legit for 3 months to make millions. Instead his lazy ass settles for some garbage tweets and pays off a $100k debt to one of his vegas lawyers. What a dumb, lazy CEO. Have fun with this crap stock.
Dumbest CEO ever. Garbage tweets. Laziest bum CEO out there. Golden opportunity and he blows it for a measly $100k. Moron
The guy is a complete moron. Bitcoin goes from $1500 to $2500 in two weeks time and all this dumbass does is post a tweet. What a lazy bum. Get your filings up to date. Make this shell scam "legit" for 3 months, drive up the stock, sell millions of $ worth of worthless stock, then disappear. The guy is too dumb to execute this. By fall, this opportunity is gonna be gone. He's only interested in a small time $ to payoff some stupid old debt. This midget brain can't see big enough. Completely useless idiot.
Dumbest CEO ever. Moron. Complete idiot. Btc $2,500 and he can't make this scam shell legit for 3 months to make millions. Dumbass
Bitcoin hits all-time high as talk of U.S. ETF approval intensifies
http://www.reuters.com/article/us-bitcoin-value-idUSKBN16A2FG
2,251 bitcoins per last PR. Market cap should at least triple. We'll see
Bitcoins definitely hot. $1280 record close again. Who knows where this goes but considering 2,251 bitcoins, this market cap should triple at minimum. We'll see.
Look at the last PR
Yes. And there's only a finite amount of bitcoins available. 15 million or something like that. CCTL market cap should be triple what it is today. Maybe it catches up next week? Who knows.
2,251 bitcoins @ $1,280 = $2,881,280. Market cap @ $1 million. Wow
Buy the rumor. Sell the news
Gonna gap up Monday and hit the 15's
Gonna close between 13.50-13.75
Muchos problemos
Keep shorting.
Not too hard? He worked his ass off.
Taking a $5 million purchase and getting a $1.9 billion market cap out of it after IPO ain't too shabby.
Gift price. Amazing buying opportunity.
News out. Up PM
$17.50+ coming this week. Enjoy the ride.
Maybe not but with over a year until phase 3 results, plenty of upside here. $20 October calls look tempting
H.C. Wainwright analyst Andrew Fein notes that Lundbeck announced that its idalopirdine missed its primary and secondary endpoints in the STARSHINE Phase 3 study in mild/moderate Alzheimer's disease. However, Fein says that idalopirdine miss does not shake his confidence in Axovant's RVT-101 as he believes Lundbeck may have simply not been able to dose idalopirdine high enough in the Phase 3 program, which minimizes read-through to Axovant's MINDSET Phase 3 study. He continues to believe that Axovant's own experimental Alzheimer's therapy is well positioned for a win. Fein reiterates a Buy rating and $35 price target on Axovant's shares.
Piper Jaffray analyst, Charles Duncan, reiterated his Overweight rating on shares of Axovant Sciences (NYSE: AXON) after shares traded off when competitor, Lundbeck, announced that its first Phase III data with idalopirdine in Alzheimer’s missed the primary endpoint.
Idalopirdine shares the putative 5-HT6 antagonist MOA with Axovant’s RVT-101 but the analyst doesn't believe this result has predictive value for the ongoing '101 Phase III. Therefore he continues to see potential for this target in AD.
Key differences between the two candidates and Phase III programs:
-idalopirdine faced challenges on liver toxicity and potency
-this drug profile and protocol prioritized speed over thoroughness
In contrast, the analyst sees RVT-101 as the best-in-class 5-HT6 candidate and thinks its MINDSET trial is well designed to show clinical benefit. In addition, Axovant has already made significant progress on enrollment and in advance of 2017 results.
No change to the price target of $32.
A spokesman for Axovant told CNBC that the results from Lundbeck's study were expected and that "weak efficacy" in their trial "is not surprising to" Axovant.
"By contrast, the objective of our Phase 3 1150-patient MINDSET study is to confirm the results of a 684-patient Phase 2 study that demonstrated statistically significant improvements on cognition and function," he said. "Based on today's news, and subject to FDA approval, intepirdine could now be the first drug of its class to be approved for the treatment of mild-to-moderate Alzheimer's disease – potentially becoming the first approved treatment for this disease since 2003."
Shorts gonna burn. May get squeezed to $20 next week
AXON will be back to $17+ in no time
Axovant says not surprised by Lundbeck study outcome, Bloomberg reports Axovant Sciences, in an emailed statement to Bloomberg, said the idalopirdine study outcome reported by competitor Lundbeck was expected. Axovant added that they think their own drug, inteperdine, could be the first drug of its class to be approved, according to Bloomberg.
Hope it bounces nicely.
CNBC said some other company had bad results in a trial which is very similar to the trial axon is doing
In at 14.16
This stock has been very educational and profitable for me. Thank you all.
Nice! Hoping to do the same tomorrow but unsure what's gonna happen
:)